Clinical profile and management of patients with pediatric inflammatory multisystem syndrome – temporally associated with SARS-CoV-2 – single-center experience
DOI:
https://doi.org/10.15584/ejcem.2022.1.2Keywords:
COVID-19, KawaCOVID, Kawasaki disease PIMS-TS, MIS-C, SISCoVAbstract
Introduction and aim. Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) is a new condition that has emerged in children during the COVID-19 pandemic. Many clinical signs and symptoms resemble those found in Kawasaki disease (KD).
Material and methods. The following data were considered: clinical presentation, comorbidities, laboratory findings, abnormalities in additional tests, exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the child and his family members, applied treatment and return to full health.
Results. In the presented study nineteen children were analyzed. Fever was a universal finding in our group and it’s mean duration was 7 days (range 5-9). Other common symptoms included abdominal pain and severe weakness (in 89.5%), rash and conjunctivitis (in 84.2%), vomiting (in 73.7%) and mucous membrane involvement (in 63.2%). In nearly half of cases, echocardiography revealed fluid in the pericardial sac and left ventricular systolic dysfunction (in 52.6% and 47.4% respectively). 21.1% of patients had coronary artery abnormalities. 26,3% of the children required treatment with dopamine and/or milrinone. In 15.7% ICU admissions and assisted ventilation was necessary. No deaths were recorded.
Conclusion. One should bear in mind that PIMS-TS can mimic KD, appendicitis and meningitis, which may pose a diagnostic challenge.
Downloads
References
Nakra NA, Blumberg DA, Herrera-Guerra A, et al. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. Children (Basel). 2020;7(7):69.
Dhar D, Dey T, Samim MM. et al. Systemic inflammatory syndrome in COVID-19-SISCoV study:
Pouletty M, Borocco C, Ouldali N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Annals of the rheumatic diseases. 2020;79(8):999-1006.
Choi SH, Kim HW, Kang JM, et al. Epidemiology and clinical features of coronavirus disease 2019 in children. Pediatr Infect Vaccin. 2020;27:11-23.
Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med. 2020;383:347-358.
Belot A, Antona D, Renolleau S, et al. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. Euro Surveill. 2020;25(22): 2001010.
Gkoutzourelas A, Bogdanos D, Sakkas I. Kawasaki Disease and COVID-19. Mediterr Journal of Rheumatology. 2020;31(supl 2):268-274.
Valverde I, Singh Y, Sanchez-de-Toledo J, et al. Acute Cardiovascular Manifestations in 286 Children With Multisystem Inflammatory Syndrome Associated With COVID-19 Infection in Europe. Cirrculation. 2021;143(1):21-32.
Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi. 1967;16(3):178-222.
Esteve-Sole A, Anton J, Pino-Ramírez RM, et al. Similarities and differences between the immunopathogenesis of COVID-19-related pediatric inflammatory multisystem syndrome and Kawasaki disease. J Clin Invest. 2021;131(6):e144554.
Consiglio CR, Cortugno N, Sardh F, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell. 2020;183:1-14.
Kabeerdoss J, Pilania RK, Karkhele R, et al. Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations, and management. Rheumatol Int. 2021; 41:19-32.
Rowley, A. H. Understanding SARS-CoV-2-related multisystem inflammatorysyndrome in children. Nat Rev Immunol. 2020;20:453-454.
Gruber CN, Patel RS, Trachtman R, et al. Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell. 2020;183(4):982-995.e14.
Suzuki J, Abe K, Matsui T, et al. Kawasaki Disease Shock Syndrome in Japan and Comparison With Multisystem Inflammatory Syndrome in Children in European countries. Front Pediatr. 2021;9:625456.
Roe K. A viral infection explanation for Kawasaki disease in general and for COVID-19 virus-related Kawasaki disease symptoms. Inflammopharmacology. 2020;28:1219-1222.
Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS‐C) Associated with SARS‐CoV‐2 and Hyperinflammation in COVID‐19. Version 2. Arthritis Rheumatol. 2020;72:1791‐1805.
World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19. https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19. Accessed on January 29, 2021.
Centers for Disease Control and Prevention (CDC). Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19).
Harwood R, Allin B, Jones CE, et al. PIMS-TS National Consensus Management Study Group. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health. 2020;S2352-S4642(20):30304-30307.
de Graeff N, Groot N, Ozen S, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease – the SHARE initiative. Rheumatology (Oxford). 2019;58(4):672-682.
Yasuhara J, Watanabe K, Takagi H, Naokata S, Kuno T. COVID‐19 and multisystem inflammatory syndrome in children: A systematic review and meta‐analysis. Pediatric Pulmonoogy. 2021;56(5):837-848.
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association [published correction appears in Circulation. 2019;140:e181–e184]. Circulation. 2017; 135:927-999.
Dhar D, Dey T, Samim MM, et al. Systemic inflammatory syndrome in COVID-19–SISCoV study: systematic review and meta-analysis. Pediatr Res. 2021. doi: 10.1038/s41390-021-01545-z
Suzuki J, Abe K, Matsui T, et al. Kawasaki Disease Shock Syndrome in Japan and Comparison With Multisystem Inflammatory Syndrome in Children in European countries. Front. Pediatr. 2021;19:625456.
Kabeerdoss J, Pilania RK, Karkhele R, et al. Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations, and management. Rheumatol Int. 2021;41:19-32.
Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771-1778.
Fouriki A, Fougère Y, De Camaret C, et al. Case Series of Children With Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in Switzerland. Front. Pediatr. 2021;8:594127.
Miller J, Cantor A, Zachariah P, Ahn D, Martinez M, Margolis K. Gastrointestinal Symptoms as a Major Presentation Component of a Novel Multisystem Inflammatory Syndrome in Children That Is Related to Coronavirus Disease 2019: A Single Center Experience of 44 Cases. Gastroenterology. 2020;159:1571-1574.
Chen TH. Neurological involvement associated with COVID-19 infection in children. J Neurol Sci. 2020;418:117096.
Fernández-Cooke E, Grasa CD, Domínguez-Rodríguez S, et al. Prevalence and Clinical Characteristics of SARS-CoV-2 Confirmed and Negative Kawasaki Disease Patients During the Pandemic in Spain. Front Pediatr. 2021;8:617039.
Yeo WS, Ng QX. Distinguishing between typical Kawasaki disease and multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2. Med Hypotheses. 2020;144:110263.
Okada Y, Minakami H, Tomomasa T, et al. Serum procalcitonin concentration in patients with Kawasaki disease. J Infect. 2004;48(2):199-205.
Korczowski B, Mroczkowska-Juchkiewicz A, Papierkowski A. High serum procalcitonin concentration in Kawasaki disease. Med Sci Monit. 1998;4(6):CS1072-1074.
Belhadjer Z, Auriau, J, Méot M et al. Addition of Corticosteroids to Immunoglobulins Is Associated With Recovery of Cardiac Function in Multi-Inflammatory Syndrome in Children. Circulation. 2020;142:2282-2284.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
